An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer.
An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer.
复制标题
DOI：
10.1158/2326-6066.cir-13-0115
复制
发表时间：
2013-12
影响因子：
10.1
通讯作者：
Formenti SC
中科院分区：
文献类型：
--
作者：
Golden EB;Demaria S;Schiff PB;Chachoua A;Formenti SC
事后证据表明，当与抗细胞毒性t淋巴细胞抗原-4单克隆（CTLA-4）抗体联合使用时，靶向肿瘤放射治疗可在非靶向肿瘤中引发免疫介导的离靶效应。在免疫原性差的临床前肿瘤模型和转移性黑色素瘤患者中，同步放疗和ipilimumab（一种人单克隆抗ctla -4抗体）诱导免疫介导的体外效应。然而，对于转移性肺腺癌患者，尚无此类报道。我们报告了在放疗和伊匹单抗治疗难治性肺癌患者的第一个体外反应。治疗后观察到肿瘤浸润性细胞毒性淋巴细胞增加，肿瘤消退和肿瘤标志物正常化。同时放疗和伊匹单抗治疗一年后，患者无疾病迹象。
A posteriori evidence suggests that radiotherapy to a targeted tumor can elicit an immune-mediated abscopal (ab-scopus, away from the target) effect in non-targeted tumors, when combined with an anti-cytotoxic T-lymphocyte antigen-4 monoclonal (CTLA-4) antibody. Concurrent radiotherapy and ipilimumab (a human monoclonal anti-CTLA-4 antibody) induced immune-mediated abscopal effects in poorly immunogenic pre-clinical tumor models and metastatic melanoma patients. However, no such reports exist for patients with metastatic lung adenocarcinoma. We report the first abscopal response in a treatment-refractory lung cancer patient treated with radiotherapy and ipilimumab. A post-treatment increase in tumor-infiltrating cytotoxic lymphocytes, tumor regression, and normalization of tumor markers was observed. One year after treatment with concurrent radiotherapy and ipilimumab the patient is without evidence of disease.